# About Tesa Compound: An Independent Tesamorelin Research Digest

> Tesa Compound is an independent editorial project that publishes structured, cited summaries of the peer-reviewed tesamorelin research literature. Not a clinic, not a vendor.

An independent editorial project that files the tesamorelin literature as a structured, cited research record.

## What this site is

Tesa Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site exists to do one thing well: read the tesamorelin record straight and file it as typed, verifiable fields. Tesamorelin is, unusually for a research peptide, a compound with a real regulatory dossier — an FDA approval (NDA 022505), an ATC code, a defined chemical identity, and a body of human trials that each report population, dose, route, outcome, and a p-value. That structure is what this project surfaces: each finding as a record with a status and a source, so a reader can see not only what the studies found but exactly where each claim comes from.

## The 'compound' in the name

The word "compound" in this site's name is editorial framing — the measured, structured register of a research data console — not a claim about services. We do not compound, dispense, or supply tesamorelin in any form, and nothing here is for sale. The name describes the posture the publisher takes toward the literature: a structured digest of the evidence, read precisely.

We hold a clear line between description and recommendation. We describe what was administered to whom, at what dose, by what route, and what was measured. We do not tell anyone to take anything. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; every other use is off-label, and research-grade material is not the approved finished product.

## How we handle accuracy

Every quantitative claim on this site is tied to a numbered citation in the reference register, drawn from PubMed-indexed journals, the FDA prescribing label, the NIH LiverTox monograph, and ClinicalTrials.gov-registered trials. Where the evidence is strong — the reproduced visceral-fat reduction in HIV-associated lipodystrophy — we say so plainly. Where it is absent — large non-HIV fat-loss trials, long-term oncologic safety — we mark the gap rather than fill it. A digest that flags its own limits is the only kind worth reading. Common reader questions are gathered, each answered with its source, in our [frequently asked questions](/faq).

---

The tesamorelin literature read as a validated record — every figure typed to its field and carried back to its study, the FDA scope (HIV-associated lipodystrophy only), the labeled contraindications, and the off-label edge surfaced as the record's leading status; a digest that flags before it reports, never a clinic, a vendor, or a prescription.